pharmacy daily for wed 05 aug 2015 - primary care consultation, one billion erx scripts, 599 shpa...
TRANSCRIPT
8/20/2019 Pharmacy Daily for Wed 05 Aug 2015 - Primary care consultation, One billion eRx scripts, 599 SHPA abstracts, He…
http://slidepdf.com/reader/full/pharmacy-daily-for-wed-05-aug-2015-primary-care-consultation-one-billion 1/4
Wednesday 05 Aug 2015 PHARMACYDAILY.COM.AU
Pharmacy Daily Wednesday 5th August 2015 t 1300 799 220 w www.pharmacydaily.com.au page 1
One Seamless
Software Solution 5/6CPA^
ClinicalInterventions
MedsCheckDAA
Detect
Admin
Modules Adverse
Event
ScriptReminders
Leave
Certificate
ScriptRenewals
MedicationReminders
Patient
Plan
Patient
Adherence New toTherapy
Compliance ProfessionalFees*
Patient
Services Blood
Pressure
Inhaler
Technique
Health
Check
^Subject to 6CPA guidelines. *Refer to program protocol. GuildLink Pty Ltd. MAR-82
GuildCare is simple to use, records & reports everything,
enabling patient review.
It integrates with dispense software & pre-populates
patient details & medication history, saving time.
5/6CPA reporting claims is easy.
MemoCare enables you to SMS, email or voice call patients.
Unlike other programs, you will always retain your patients’
details, safeguarding the future of your pharmacy.
You can easily interact with patients’ GPs using MemoCare.
for Professional Services
1300 647 492
[email protected] more >
healthnotes.com.au
1 MILLIONENROLLEDCUSTOMERS
Today’s issue of PDPharmacy Daily today has
three pages of news plus a full
page with the MIMS monthly
update for Aug.
$4m Mayne grant
MAYNE Pharma Group will bethe recipient of up to $4 million
in government funding aer a
successful applicaon under the
Next Generaon Manufacturing
Investment Program.
The money will help support
the installaon of an $11 million
large scale state-of-the-art uid
bed spray coater at the company’s
manufacturing facility in Salisbury,
South Australia.
CEO Sco Richards said the
expansion of Mayne’s modied-
release manufacturing capabilitywould help handle expected growth
in current products as well as the
commercialisaon of other items
currently in the pipeline.
He said Mayne has directed more
than 80% of its Australian-based
research and development spend
to the development of advanced
oral drug delivery formulaons.
“Today more than half of global
pharmaceucal prescripon
revenues come from dose forms
that require more than simple
immediate-release tablets,” he said.
599 SHPA abstractsTHE upcoming 41st Society of
Hospital Pharmacists of Australia
Naonal Conference has already
generated a strong response, with
599 abstracts submied in the lead-
up to the event which takes place in
Melbourne 03-06 Dec this year.
Medicines Management 2015
will once again provide a showcase
or innovave research, with SHPA
president Michael Dooley saying
he avalanche of submissions
shows how keen pharmacists,
echnicians, interns and students
re to share their work, and how
passionate they are about their
profession”.
This year the program has been
extended to three days, with
he “paent’s and praconer’s
ourney” as the focus - for moredetails see mm2015shpa.com.
Primary care consultationHEALTH minister Sussan
Ley yesterday released a new
discussion paper developed by
the Primary Health Care Advisory
Group (PHCAG) (PD 05 Jun), with
opons for health system reform.
The discussion paper suggests
a range of possibilies such as
enrolling paents to a single
provider who would coordinate
mul-disciplinary care, seng
chronic disease payments for a
dened package of care rather
than remuneraon for individualservices and adopng internaonal
methods of best pracce.
Ley said it was essenal to review
chronic disease health care because
Medicare items covering these
areas had surged almost 17% in
2013-14 to over $587 million.
“We are commied to nding
beer ways to care for people with
chronic and complex condions and
ensure they receive the right care,
in the right place, at the right me,”
the minister said.
Guild president George Tambassis
said the Guild welcomed the public
consultaon process.
With more than 5,450 community
pharmacies spread across the
country there was an “opportunity
to engage people along the health
spectrum and hard-to-reach
populaons who do not use other
health services, parcularly in rural
and remote locaons,” he said.
“The me is right for beer
and broader use of community
pharmacy as a primary health care
resource and as part of the widerprimary health care team”.
The PHCAG will now seek feedback
via an online survey to launch
tomorrow, as well as public sessions
in Sydney, Dubbo, Melbourne,
Geelong, Hobart, Perth, Brisbane,
Cairns, Rockhampton, Adelaide,
Alice Springs, Darwin and Broome.
A naonwide webcast will also
take place on Fri 21 Aug, and
aer the consultaon period
the PHCAG will develop specic
recommendaons by the end of
the year - see health.gov.au.
8/20/2019 Pharmacy Daily for Wed 05 Aug 2015 - Primary care consultation, One billion eRx scripts, 599 SHPA abstracts, He…
http://slidepdf.com/reader/full/pharmacy-daily-for-wed-05-aug-2015-primary-care-consultation-one-billion 2/4
Wednesday 05 Aug 2015 PHARMACYDAILY.COM.AU
Pharmacy Daily Wednesday 5th August 2015 t 1300 799 220 w www.pharmacydaily.com.au page 2
Sister Sam joins PricelinePRICELINE Pharmacy
has announced that
Australian model
Samantha Harris
(pictured) has become
the newest Priceline
Pharmacy Sister, joining
actress Ada Nicodemou,
media personality Ita
Burose and the enre
Adelaide Thunderbirds
Netball team.
With a 12 month
contract, Harris will
commence her role
immediately, helping
launch Priceline
Pharmacy’s Fesval of
Beauty campaign this
month.
Harris was previouslyan ambassador for
Priceline’s You Beauty
campaign in 2014, with
the company’s gm of
markeng, Mark O’Keefe,
saying “our past work
with her has been hugely
successful and shown
that she is a perfect t
for our brand”.
– can we turn up the heaton experiential education?
2015 Colloquium
25 August, Canberra
REGISTER NOW!
The secretingredient
Free registration for
students and interns
Free live streaming
of all sessions
National and
international speakers
CELEBRATING
504 MEMBERS
Our continued focus on providing independent pharmacy with business solutionsthat make operating their pharmacy easier is the reason why we are the largesttruly independent pharmacy group in Australia.
We would like to thank our members and industry partners for their support.
Become a member ofPharmacy Alliance and
experience the differencein your pharmacy’sperformance.
(03) 9860 3300www.pharmacyalliance.com.au
Tighten up CAM callTIGHTER regulaon and more
research into complementary and
alternave medicines (CAM) for
menopausal symptoms is required,
according to a report in the Medical
Journal of Australia this week.
Gynaecologist at the Women’s
Health and Research Instute of
Australia, Associate Professor John
Eden, suggested a similar concept
to the Heart Foundaon’s “Tick”
program to ensure treatments are
standardised and evidence-based.
He was responding to an MJA
study which found Australian
women are using CAMs for
managing vasomotor symptoms of
menopause (VMS).
However MJA Insight also cited
Professor Martha Hickey fromthe Royal Women’s Hospital
in Melbourne, who said it was
important to recognise there was
no ‘cookie cuer’ approach.
“It’s become fashionable to say
that all CAMs are rubbish.
“But the fact is, women are
worried about [side eects of]
hormone replacement therapy -
and righully so,” she said.
SSRI warning
NEW Zealand’s Centre forAdverse Reacons Monitoring has
issued an alert under the Trans-
Tasman Early Warning System aer
receiving a report of a paent who
experienced serotonin syndrome
aer taking just one dose of
escitalopram.
The paent experienced
symptoms within 24 hours of taking
the dose, and while the reacon
is a predictable consequence
of excess serotonin, the report
“highlights that this syndrome
may occur aer only one doseof an SSRI, without any other
concomitant medicaon”.
Guild member survey
PHARMACY Guild members arebeing asked to complete a brief
urvey so the organisaon can gain
nsight into their communicaon
preferences, including how they
would like to receive updates and
what types of informaon they
would like to see from the Guild, as
well as where they currently source
nformaon and advice.
Members can take part in
he brief 8-queson survey by
ontacng their local branch, or by
ompleng it online - CLICK HERE.
One billion eRx scriptsERX Script exchange says
Australia “achieved a major
milestone in paent safety”
yesterday, aer reaching a total of
one billion prescripons dispensed
electronically via eRx.
Fred IT Group ceo Paul Naismith
enthused that the achievement
was “real cause for celebraon for
Australian paents, their doctors
and pharmacists,” with electronic
transfer of prescripons increasing
condence that the correct
medicaons are being dispensed,
while at the same me making
dispensing faster and ensuring
paent details are correct.
“The achievement of creang
an Australia-wide electronic
script network is a direct result
of signicant support behind
the scenes,” he said, including
cooperaon between the pharmacy
and medical professions, industry
groups, IT rms and government.
eRx conducted a survey earlier
this year, with 74% of pharmacists
saying Fih Community Pharmacy
Agreement funding for e-scripts
was “very important for their
ongoing use of electronic scripts”.
Currently pharmacies using eRx
are electronically dispensing more
than 745,000 e-scripts per day.
8/20/2019 Pharmacy Daily for Wed 05 Aug 2015 - Primary care consultation, One billion eRx scripts, 599 SHPA abstracts, He…
http://slidepdf.com/reader/full/pharmacy-daily-for-wed-05-aug-2015-primary-care-consultation-one-billion 3/4
Wednesday 05 Aug 2015 PHARMACYDAILY.COM.AU
Pharmacy Daily is Australia’s favourite pharmacy industry publicaon.
ign up free at www.pharmacydaily.com.au.
Postal address: PO Box 1010, Epping, NSW 1710 Australia
treet address: 4/41 Rawson St, Epping NSW 2121 Australia
P: 1300 799 220 (+61 2 8007 6760) F: 1300 799 221 (+61 2 8007 6769)
Part f th Trav Daiy rup f pubicas.
Publisher: Bruce Piper [email protected]
Reporter: Mal Smith
Advrsi ad Mark: Magda Herdzik [email protected]
Business Manager: Jenny Piper [email protected]
business events news
harmacy Daily is a publicaon of Pharmacy Daily Pty Ltd ABN 97 124 094 604. All content fully protected by copyright. Please obtain wrien permission to reproduce any material. While every care has been taken in the preparaon of
he newsleer no liability can be accepted for errors or omissions. Informaon is published in good faith to smulate independent invesgaon of the maers canvassed. Responsibility for editorial comment is taken by Bruce Piper.
Health, Beautyand New Products
Welcome to our weekly promoted feature
with all the latest health, beauty and new
products for pharmacy.
Suppliers wanng to promote products in
this feature should email
Just one click away from keeping up to date with all the Pharmacy Daily breaking news as it comes to hand
Follow uson social media
DISPENSARYCORNER
RUMOURS of this woman’s
demise were somewhat
exaggerated - and it caused her
signicant problems.
40-year-old Alexandria Goree
from St Louis in the USA is suing a
group of credit reporng agencies
aer spending some months
aempng to convince them that
she was alive.
According to court documentsled last week, she found a
“deceased” notaon on les
held by Experian, Equifax and
TransUnion - which explained why
she had found it fairly dicult to
get a home loan.
“Words can’t really explain how
I felt,” she said on discovering the
glitch, which had seen her having
to deal with a host of rejecons
from credit card companies and
business nanciers.
“Anything that would require
monthly payments” was aproblem: “I was only able to
purchase with cash”.
A one-leggeD chicken in the US
is about to get a new lease on life,
in the form of a prosthec limb
created on a 3-D printer.
It’s not quite in the league of
the Six Million Dollar Man, with
the rst-of-its-kind procedure
esmated to cost about $2,500.
The three-month-old chook will
undergo surgery aer presenng
at a veterinary surgery with a torntendon in her right leg.
The vet suggested either a
prosthec or euthanasia, with her
chicken-loving owner instantly
opng for the technical soluon.
“It was a no-brainer,” according
to Andrea Marn from Black
Thistle Farm near Boston.
“She needs to be able to live a
normal life,” she added.
If the procedure works Marn
plans to write a children’s book
about the experience.
Painmaster Micro-current TherapyPainmaster Micro-current Therapy supplies extremely low electrical current to the aected pain area, reachinginjured cells, potentially restoring and regenerating them to alleviate chronic pain. Painmaster is self contained,non-invasive, with no electrical sensations, lasts up to 300hrs and its cumulative eect assists in long termhealing, the company says. Painmaster is not a pain blocker but mayprovide some relief from muscle pains and spasms in the lower and
upper back, the neck, sciatic regions, tennis elbow and other joints,bromyalgia and arthritic disorders.
Stockist: 1300 558 252RRP: $45.00Website: www.painmaster.com.au
Diesel Loverdose from L’Oreal LuxeDiesel Loverdose is designed to make any woman feel irresistible. Loverdose has aoral, spicy fragrance opening with notes of star anise and mandarin, developingwith notes of sambac jasmine, licorice and gardenia petals. The fragrance driesdown with notes of amber, vanilla and woods. Cut like a diamond with many faces,the bottle is made of glass with pink amethyst highlights.
Stockist: 1300 651 991
RRP: $70.00 for 30mLWebsite: www.loreal.com.au
Head & Shoulders For Men Hair Retain ShampooHead & Shoulders for Men Hair Retain Shampoo surrounds the hair bre to protect itfrom damage and breakage caused by dandru that can lead to hair falling out withoutweighing thinner hair down. The light ingredient combination and tailored blend ofactives features anti-danru technology ZPT and menthol to cool down the scalp skinimmediately to soothe and refresh.
Stockist: 1800 028 280RRP: $6.75 for 200mL
Website: www.headandshoulders.com.au
Age Perfect Intense Nutrition Rich Repairing Night CreamL’Oréal Paris Age Perfect Intense Nutrition Rich Repairing Night Cream contains 10 oils to nourish your skin and deeply restore it with nutrientsduring sleep. The six nourishing oils include passionower oil, rosehip oil,apricot kernel oil, cameline oil, rice bran oil and corn oil. The sleep-enhancingoils include sweet orange oil, camomile oil, marjolaine oil and neroli oil. Thecream is easily absorbed deeply into the skin.
Stockist: 1300 659 359RRP: $34.85 for 50mLWebsite: www.lorealparis.com.au
8/20/2019 Pharmacy Daily for Wed 05 Aug 2015 - Primary care consultation, One billion eRx scripts, 599 SHPA abstracts, He…
http://slidepdf.com/reader/full/pharmacy-daily-for-wed-05-aug-2015-primary-care-consultation-one-billion 4/4
August 2015
NEW PRODUCTS
Daklinza (daclatasvir) is a highlyselective inhibitor of hepatitis Cvirus (HCV) nonstructural protein5A (NS5A) replication complex.
Daklinza is indicated in combinationwith other medicinal productsfor the treatment of chronic HCVinfection in adults with compensatedliver disease (including cirrhosis).The combination of Daklinza withpeginterferon alfa and ribavirin iscontraindicated in women who arepregnant or may become pregnantand men whose female partners arepregnant because of the risks of birthdefects and foetal death associatedwith ribavirin. Daklinza is alsocontraindicated in combination withdrugs that strongly induce CYP3A4
and thus may lead to lower exposureand loss of efcacy of Daklinza.Contraindicated drugs include,but are not limited to, phenytoin,carbamazepine, oxcarbazepine,phenobarbital, rifampicin, rifabutin,dexamethasone and St John’s wort(Hypericum perforatum). Daklinza isavailable as 30 mg and 60 mg tabletsin packs of 28’s.
Entyvio (vedolizumab (rch)) isa humanised IgG1 monoclonalantibody that binds to the humanα4β7 integrin and is produced
in Chinese hamster ovary cells.Entyvio is indicated in the treatmentof adult patients with moderate tosevere ulcerative colitis who havehad an inadequate response with,lost response to, or are intolerantto either conventional therapy or atumour necrosis factor-alpha (TNFα)antagonist. It is also indicated inthe treatment of adult patients withmoderate to severe Crohn’s diseasewho have had an inadequateresponse with, lost response to, orare intolerant to either conventionaltherapy or a TNFα antagonist.
Entyvio is contraindicated with activesevere infections such as sepsis,tuberculosis, opportunistic infections,and serious abscesses. Entyvio isavailable as a powder for injection ina single use vial containing 300 mgof vedolizumab.
Hizentra (normal immunoglobulin(human)) contains functionallyintact IgG with a broad spectrumof antibodies against infectiousagents. Hizentra is indicated inadults and children as replacementtherapy in primary immunodeciency
disease (PID) and symptomatichypogammaglobulinaemia secondaryto underlying disease or treatment.Hizentra is contraindicated inhyperprolinaemia type I or II.Hizentra is available as a 20%(20 g/100 mL) solution for infusionin a 5 mL, 10 mL, 20 mL and 50 mLsingle use vial.
Otezla (apremilast) an oralsmall molecule inhibitor ofphosphodiesterase 4 (PDE4),works intracellularly to modulate anetwork of pro-inammatory andanti-inammatory mediators. Otezla
is indicated for the treatment of signsand symptoms of active psoriaticarthritis in adult patients and alsofor the treatment of adult patientswith moderate to severe plaquepsoriasis who are candidates forphototherapy or systemic therapy. Itis contraindicated during pregnancyand in nursing women. Otezla isavailable as a two week titration pack(containing 4 x 10 mg tablets,4 x 20 mg tablets and 5 x 30 mgtablets for the rst week of dosetitration and 14 x 30 mg tablets forthe second week). It is also available
as a four week pack (56 x 30 mgtablets).
ProQuad (measles, mumps,rubella and varicella) is a combinedattenuated live virus vaccine.ProQuad is indicated for vaccinationagainst measles, mumps, rubella,and varicella in individuals12 months through 12 years ofage. ProQuad is contraindicatedin gelatin hypersensitivity; historyof anaphylactoid reaction toneomycin; active febrile illness withfever > 38.5ºC; active untreated
TB; family history of congenitalor hereditary immunodeciencyunless immune competencedemonstrated; primary/ acquiredimmunodeciency states includingHIV, hypogammaglobulinaemia,dysgammaglobulinaemia, cellularimmune deciency; blood dyscrasia;malignancy affecting bonemarrow, lymphatic system e.g.leukaemia, lymphoma; concomitantimmunosuppressants (excludingtopical/ low dose corticosteroids,corticosteroid replacement therapy);and pregnancy. ProQuad is available
as a single use powder for injectionvial in packs of 1’s and 10’s.
Sunvepra (asunaprevir) is aselective inhibitor of the HCVnonstructural protein 3/4A(NS3/4A) protease. It is indicatedin combination with other medicinalproducts for the treatment of chronichepatitis C virus (HCV) infectionin adults with compensated liverdisease (including cirrhosis).Sunvepra is contraindicatedin moderate to severe hepaticimpairment (Child-Pugh B or C);
decompensated liver disease;concomitant thioridazine, moderateto strong CYP3A inducers (includingphenytoin, carbamazepine,oxcarbazepine, phenobarbitone,rifampicin, rifabutin, bosentan,dexamethasone, St John’s wort,efavirenz, etravirine, nevirapine,modanil), moderate to strong
CYP3A inhibitors (includingitraconazole, ketoconazole,posaconazole, voriconazole,uconazole, clarithromycin,erythromycin, diltiazem, verapamil,atazanavir, ritonavir, darunavir/
ritonavir, fosamprenavir, indinavir,lopinavir/ ritonavir, saquinavir,cobicistat), OATP1B1 inhibitors(including cyclosporin, gembrozil);in combination with peginterferonand ribavirin, also males withpregnant female partners, women ofchildbearing potential (unless 2 formsof effective contraception used)including 6 months post-treatmentof either partner, and pregnancy.Sunvepra is available as 100 mgcapsules in packs of 56’s.
NEW INDICATIONS
Enbrel (etanercept (rch)) is nowalso indicated in the treatmentof adults with active (activedisease is dened as a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) scoreof ≥ 4), nonradiographic axialspondyloarthritis with objective signsof inammation as indicated byelevated C-reactive protein (CRP)and/or MRI change who have had aninadequate response to NSAIDs.
As Neutrafuor 5000 Plus
(sodium fuoride) delivers uoridetopically to teeth and is intended forerupted teeth in adults and childrenover the age of ten, the increaseduoride dose should not contributeto uorosis provided it is not used inan unsupervised manner in childrenunder ten years of age.
SAFETY RELATED CHANGES
Advantan (methylprednisoloneaceponate) is now contraindicatedif ulcera or atrophic skin disease ispresent.
Dizole One (fuconazole) is nowcontraindicated with coadministrationof the QT prolonging drugerythromycin.
Epilim (sodium valproate),
Epilim IV (sodium valproate) are now contraindicated in patientsknown to have mitochondrialdisorders caused by mutations in thenuclear gene encoding mitochondrialenzyme polymerase gamma (POLGeg Alpers-Huttenlocher syndrome)and in children under two years of
age who are suspected of havingPOLG related disorder.
This list is a summary of onlysome of the changes that haveoccurred over the last month. Beforeprescribing, always refer to the fullproduct information.